Searchable abstracts of presentations at key conferences in endocrinology

ea0041ep335 | Clinical case reports - Thyroid/Others | ECE2016

Orbitopathy as a manifestation of Immunoglobulin-G4-related disease – case report

Zwolak Agnieszka , Dudzinska Marta , Swirska Joanna , Malicka Joanna , Daniluk Jadwiga , Tarach Jerzy S

Introduction: Immunoglobulin-G4-related disease (IgG4RD) is a multidisciplinary problem due to plasmatic cells infiltration and areas of fibrosis in the affected tissues. In IgG4RD, elevation of serum IgG4 immunoglobulins is present. Clinically, the disease is mainly manifested as: autoimmune pancreatitis, salivary gland involvement, sclerosing cholangitis, lymphadenopathy, lachrymal gland enlargement, retroperitoneal fibrosis or orbital pseudotumor. The simultaneous involveme...

ea0041ep355 | Clinical case reports - Thyroid/Others | ECE2016

Amiodarone - induced type 2 thyrotoxicosis in patient with ESRD treated with hemodialysis

Kurowska Maria , Malicka Joanna , Bober-Palak Ewa , Lewicki Marcin , Tarach Jerzy S.

Introduction: Type 2 amiodarone-induced thyrotoxicosis (AIT2), resulting from the release of thyroid hormones, is a rarer form of side effect of this drug. Treatment of thyrotoxicosis in patients with end stage renal disease (ESRD) is difficult because hemodialysis alters renal clearance of drugs and iodine, may impact the results of assessment and treatment and can increase the medical instability of patients.Aim: The aim was to present the difficulties...

ea0041ep944 | Pituitary - Clinical | ECE2016

The prevalence of metabolic syndrome in adult patients with long-standing hypopituitarism who receive adequate supplemental therapy

Zwolak Agnieszka , Swirska Joanna , Dudzinska Marta , Kurowska Maria , Daniluk Jadwiga , Tarach Jerzy S

Introduction: Hypopituitarism is characterized by the absence of pituitary hormones. Depending on what pituitary hormones are missing and what is the etiology of hypopituitarism, its clinical manifestation varies. Apart from evident symptoms and signs of hypopituitarism due to hormonal insufficiencies, several studies reveal that long-standing hypopituitarism, including particularly absence of GH, is related to higher risk of metabolic syndrome.Objective...

ea0041ep1069 | Thyroid (non-cancer) | ECE2016

The efficacy of Radioiodine Therapy in Patients with Graves’ Disease

Dabrowska Anna , Kijek Jolanta , Tarach Jerzy , Torun-Jurkowska Anna , Chrapko Beata , Kurowska Maria

Introduction: Radioiodine (RAI) has been used for the treatment of Graves’ hyperthyroidism since 1940s. It is relatively safe and considered as one of the definitive therapies. Achievement of hypothyroidism or euthyroidism is defined as a successful therapy.Methods: The study was conducted in 366 patients (80.60% of women) with Graves’ disease (GD), aged 46.76±13.52 years. We analyzed retrospectively hormonal and imaging findings (scintigr...

ea0041ep1081 | Thyroid (non-cancer) | ECE2016

The efficacy of radioiodine therapy in patients with hyperfunctioning thyroid nodules

Dabrowska Anna , Kijek Jolanta , Tarach Jerzy , Torun-Jurkowska Anna , Chrapko Beata , Kurowska Maria

Introduction: Radioiodine (RAI) is used as a definitive therapy of hyperthyroidism due to toxic adenoma (TA) as well as toxic multinodular goiter (TMG). Achievement of hypothyroidism or euthyroidism is defined as a successful therapy.Methods: The study was conducted in 666 patients – 484 with TA and 182 with TMG (85.58% of women), aged 56.19±13.88 years. We analyzed retrospectively hormonal and imaging findings (scintigraphy, ultrasonography), ...

ea0037ep666 | Pituitary: basic and neuroendocrinology | ECE2015

Dose interval injection extension and costs of lanreotide Autogel 120 mg used in routine acromegaly care in Poland: 2 years data from Lanro study

Orlewska Ewa , Kos-Kudla Beata , Sowinski Jerzy , Sworczak Krzysztof , Zgliczynski Wojciech

Objective: To determine the percentage of patients with acromegaly who received lanreotide Autogel 120 mg (ATG120) in extended duration interval and to evaluate the mean costs of ATG120 administered as part of routine care in Poland.Methods: National, multicentre, non-interventional, observational prospective study with 2-years’ time horizon. The study population consisted of adult acromegaly patients who received at least three injections of ATG120...

ea0035p9 | Adrenal cortex | ECE2014

Hormonal and clinical correlations in nonfunctional adrenal incidentalomas

Kiedrowicz Bartosz , Poblocki Jakub , Koziolek Monika , Syrenicz Justyna , Lubikowski Jerzy , Syrenicz Anhelli

Introduction: The prevalence of incidentally found adrenal tumors – adrenal incidentalomas (AI) – in imaging procedures and autopsy series is up to 4.5–8.7%. Endocrine and clinical evaluation is carried out to diagnose hormonal function or malignancy of the tumors. Nonfunctional adenomas comprise about 80% of AI. The aim of the study was to identify possible association between various clinical, hormonal and radiological features of nonfunctional AI.<p class...

ea0035p223 | Clinical case reports Pituitary/Adrenal | ECE2014

Ineffectiveness of temozolomide in aggressive dopamine-agonist resistant prolactinoma and type 3 silent somatotropinoma

Kurowska Maria , Malicka Joanna , Tarach Jerzy S , Zielinski Grzegorz , Swiatkowska-Stodulska Renata , Sworczak Krzysztof

Introduction: Temozolomide (TMZ) can be administered as the last therapeutic option for aggressive pituitary tumors. Dopamine-agonist resistant prolactinomas are relatively frequent and remain a serious therapeutic problem. GH expressing atypical adenomas are rare and their positive response to TMZ is low. In a general opinion a lack of response to TMZ after three cycles predicts the treatment resistance.The aim of the study was presentation of two patie...

ea0035p224 | Clinical case reports Pituitary/Adrenal | ECE2014

Cushing's disease in patient with primary empty sella

Kurowska Maria , Malicka Joanna , Zielinski Grzegorz , Tarach Jerzy S , Maksymowicz Maria , Denew Piotr

Introduction: The empty sella syndrome (ESS) is defined as the penetration of the subarachnoid space into intrasellar region. In ESS pituitary hormonal function is usually normal, but several, mostly subtle, hormonal abnormalities have been also reported. The coexistence of Cushing’s disease and primary empty sella is very rare.Objective: The presentation of an exceptional case of a patient with Cushing’s disease associated with primary empty s...

ea0035p225 | Clinical case reports Pituitary/Adrenal | ECE2014

Temozolomide-induced marked regression of invasive Crooke's cells corticotropinoma in patient with Cushing's disease

Kurowska Maria , Malicka Joanna , Zielinski Grzegorz , Tarach Jerzy S , Maksymowicz Maria , Denew Piotr

Introduction: Crooke’s cells are normal corticotrophs with cytoplasmic accumulation of cytokeratin filaments in response to glucocorticoids excess. Crooke’s cell corticotropinomas are the unique cause of Cushing’s disease. Nearly all of them are invasive macroadenomas, generally aggressive, refractory to conventional therapy, with high recurrence rate.Aim of the study was to present a case study of a patient with Cushing’s disease cau...